Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBP-V001
- Development stage
- Phase 1
- Lead developer
- Kentucky BioProcessing
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
KBP-V001 is an investigational quadrivalent seasonal influenza vaccine developed by Kentucky BioProcessing. It was evaluated in a randomized, observer-blinded, placebo-controlled Phase 1 study in healthy adults and uses a *Nicotiana benthamiana* plant-based vaccine-production platform. The product is intended to prevent influenza by eliciting immune responses to antigens from four influenza vaccine strains. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04439695))
- Other names
- intermediate dose-KBio Inc-influenzaquadrivalent influenza vaccine (KBP)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on KBP-V001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBP-V001.